JNJ 17305600
Alternative Names: JNJ-17305600Latest Information Update: 16 Jul 2016
At a glance
- Originator Johnson & Johnson
- Class Antipsychotics
- Mechanism of Action Glycine transporter 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Schizophrenia
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Schizophrenia in USA